ACLX earnings analysis
What we found in ACLX's 10-K: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The 10-K/A emphasizes clinical and commercial progress for lead product anito-cel (the company states it “submitted our first BLA for anito-cel” and prepared for a potential 2026 launch) and the strategic partnership/capital support from Kite (upfront payments of $225 million in Feb 2023 and $85 million in Nov 2023, plus a $68.3 million milestone in 2024). The filing also confirms a pending acquisition by Gilead via a tender offer (Offer Price $115.00 per share plus one CVR worth $5.00 contingent on a milestone) and notes corporate scale (220 employees as of March 1, 2026; 58,479,812 shares outstanding as of Feb 20, 2026).
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- BLA submission and launch preparation
- Management states it “submitted our first BLA for anito‑cel” and that the program is positioned for a potential 2026 launch (filed as part of the Compensation Discussion & Analysis).
- Material collaboration cash received from Kite
- Under the Kite collaboration the company received upfront payments of $225 million (Feb 2023) and $85 million (Nov 2023) and recorded a $68.3 million clinical milestone payment in 2024; total potential milestone pool cited is approximately $3.9 billion.
- Pending acquisition at a substantial per‑share price
- The Merger Agreement with Gilead contemplates a tender offer of $115.00 per share plus one CVR (a $5.00 contingent payment) as described in Item 13; the Offer commenced March 6, 2026 and will initially remain open for a minimum of 20 business days.
- Board and talent scale
- Filing reports 220 full‑time employees as of March 1, 2026 and discloses board composition (8 directors, seven independent) and diversity metrics (Total Company: 55% female; 77% diverse).
- Significant equity incentives aligned to launch
- 2025 RSU grants to executives: CEO received 223,964 RSUs (grant date fair value $16,799,540); CFO received 82,120 RSUs (grant date fair value $6,159,821).
- Public valuation reference
- The aggregate market value of shares held by non‑affiliates was reported as approximately $3.2 billion based on the June 30, 2025 closing price.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Merger completion and timing uncertainty
- The Merger Agreement’s tender offer structure means deal completion depends on the offer and other conditions; the filing states the Offer “will initially remain open for a minimum of 20 business days,” highlighting timing and conditionality risk.
- CVR contingent payment uncertainty
- Consideration includes one CVR (a contingent $5.00 payment) payable only upon achievement of a specified milestone under the CVR Agreement, so a portion of consideration is contingent and may pay nothing if milestone not met.
- Dependency on Kite collaboration outcomes
- Company’s BLA and launch preparation are tied to the Kite collaboration; the filing discloses prior payments ($225M and $85M) and that Arcellx is eligible for up to approximately $3.9 billion in milestone payments, indicating material dependence on the partner’s execution.
- Potential cash outflow for tax mitigation
- Pursuant to the Merger Agreement the company may pay up to an aggregate of $25,000,000 (inclusive of any gross‑up payments) to employees to facilitate payment of certain excise taxes, creating a potential cash use tied to the transaction.
- Execution risk on manufacturing and launch readiness
- In the 2025 bonus plan disclosure, Manufacturing Goals carried a 25% weight and Clinical Program Goals 35% weight; the company highlights completing vector activities and IND amendment submissions, implying missed execution on these priorities would materially affect launch readiness.
- Concentration of equity and pay‑for‑performance optics
- Executive pay is skewed to equity: CEO total 2025 compensation was $18,183,311 and the CEO received RSUs with grant date fair value $16,799,540 in 2025, which could raise governance or retention scrutiny pre‑ or post‑transaction.
What they said about what is next.
The 10‑K/A and the incorporated CD&A discuss clinical/regulatory milestones and launch preparation but do not provide explicit numeric annual revenue or EPS guidance; management continues to defer specific annual outlook to earnings press releases/calls.
The filing reads about the same as the one before it.
What came before.
- 10-K · February 26, 2026
- Arcellx’s 2025 10-K highlights a strong clinical readout and regulatory progress for lead program anito-cel (96% ORR; BLA submitted Dec 23, 2025 and accepted by FDA on Feb 20, 2026 with a PDUFA date of Dec 23, 2026) and…
- 10-Q · May 8, 2025
- Arcellx reported Q1 collaboration revenue of $8.129 million (vs. $39.256 million in Q1 2024) and a net loss of $62.270 million ($1.13 per share) as operating expenses rose to $77.027 million. Cash, cash equivalents and…
- 10-Q · August 8, 2024
- Arcellx reported collaboration revenue of $27.384M for Q2 2024 and a net loss of $27.202M (EPS -$0.51). Revenue roughly doubled year-over-year (Q2 2023: $14.302M) and the company finished the quarter with $646.8M in…
- 10-Q · May 9, 2024
- Arcellx reported Q1 2024 collaboration revenue of $39,256,000 (vs. $17,912,000 in Q1 2023), driving a material revenue beat and narrowing net loss to $7,198,000 (EPS -$0.14) from a $27,344,000 loss (EPS -$0.58) a year…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing ACLX makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever